Alentis Therapeutics
About:
ALENTIS Therapeutics is a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer.
Website: https://alentis.ch/
Top Investors: Bpifrance, HTGF | High-Tech Gruenderfonds, OrbiMed, RA Capital Management, Innosuisse
Description:
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech investigating novel therapeutics for CLDN1+ cancers. Alentis is the pioneering business in the use of anti-CLDN1 ADCs and antibodies to modify and reverse the progression of certain diseases.
Total Funding Amount:
$365M
Headquarters Location:
Basel, Basel-Stadt, Switzerland
Founded Date:
2019-01-01
Founders:
Neil Goldsmith, Thomas Baumert
Number of Employees:
51-100
Last Funding Date:
2024-11-12
IPO Status:
Private
Industries:
© 2025 bioDAO.ai